Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 2:44 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 433–456 of 1,629 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Gemzar Clear all

Conditions: Recurrent Non-Muscle Invasive Bladder Carcinoma, Stage 0a Bladder Cancer AJCC v8, Stage I Bladder Cancer AJCC v8
Interventions: BCG Solution, Biopsy of Bladder, Cystoscopy, Computed Tomography, Magnetic Resonance Imaging, Biospecimen Collection, Transurethral Resection of Bladder Tumor, Gemcitabine; Biological · Procedure · Drug
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older
Enrollment: 330 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 60
States / cities: Birmingham, Alabama • Fairbanks, Alaska • Gilbert, Arizona + 52 more

Conditions: Pancreatic Neoplasms
Interventions: LY2603618, Gemcitabine; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 157 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 16
States / cities: Jacksonville, Florida • Athens, Georgia • Macon, Georgia + 13 more

Conditions: Bladder Cancer, Renal Pelvis Cancer, Ureter Cancer
Interventions: gemcitabine and split-dose cisplatin plus escalating doses of continuous Everolimus (RAD001); Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2016
U.S. locations: 1
States / cities: New York, New York

Conditions: Advanced Solid Tumors, Lymphoma
Interventions: AG-270, docetaxel, nab-paclitaxel, gemcitabine; Drug
Lead sponsor: Institut de Recherches Internationales Servier; Other
Eligibility: 18 Years and older
Enrollment: 123 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 6
States / cities: New Haven, Connecticut • Boston, Massachusetts • New York, New York + 1 more

Conditions: Advanced Solid Tumors, Ovarian Cancer, Endometrial Cancer, Cholangiocarcinoma, CNS Tumor, Breast Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma, Carcinosarcoma, Ovarian
Interventions: PHST001, Paclitaxel, Topotecan, Doxorubicin, FOLFIRI, FOLFOX, Gemcitabine, Mirvetuximab Soravtansine, Trastuzumab Deruxtecan; Biological · Drug
Lead sponsor: Pheast Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 426 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 20
States / cities: Beverly Hills, California • Los Angeles, California • Palo Alto, California + 15 more

Conditions: Pancreas Cancer, Pancreatic Cancer, Adenocarcinoma of the Pancreas, Pancreas Adenocarcinoma, Pancreatic Adenocarcinoma
Interventions: Gemcitabine, Stereotactic Radiosurgery; Drug · Radiation
Lead sponsor: Cooper Norcross Health; Other
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2013
U.S. locations: 1
States / cities: Camden, New Jersey

Conditions: Pancreatic Cancer
Interventions: Gemcitabine, Abraxane, Radiation Therapy; Drug · Radiation
Lead sponsor: Olugbenga Olowokure; Other
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Pancreatic Cancer
Interventions: MVT-5873, modified FOLFIRINOX (mFOLFIRINOX), gemcitabine + nab-paclitaxel; Drug
Lead sponsor: BioNTech Research & Development, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 118 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2025
U.S. locations: 5
States / cities: Scottsdale, Arizona • Los Angeles, California • Sarasota, Florida + 2 more

Conditions: Pancreatic Cancer Metastatic, Pancreatic Cancer Stage IV, Stage IV Pancreatic Cancer
Interventions: SBP-101, nab-paclitaxel, Gemcitabine Injection; Drug
Lead sponsor: Panbela Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 3
States / cities: La Jolla, California • Gainesville, Florida • Rochester, New York

Conditions: Pancreatic Cancer
Interventions: Vidaza; Drug
Lead sponsor: University of Oklahoma; Other
Eligibility: 18 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 1
States / cities: Oklahoma City, Oklahoma

Conditions: Ovarian Cancer, Testicular Germ Cell Tumor
Interventions: gemcitabine hydrochloride, paclitaxel; Drug
Lead sponsor: Eastern Cooperative Oncology Group; Network
Eligibility: 15 Years to 120 Years
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1999
U.S. locations: 18
States / cities: Denver, Colorado • Chicago, Illinois • Urbana, Illinois + 13 more

Conditions: Tumors, Lymphoma
Interventions: Oncaspar & Gemzar; advanced and/or solid tumors and lymphoma; Drug
Lead sponsor: Enzon Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 3
States / cities: Scottsdale, Arizona • Omaha, Nebraska • San Antonio, Texas

Conditions: Ovarian Cancer, Peritoneal Carcinomatosis, Fallopian Tube Cancer
Interventions: Olvi-Vec, Platinum-doublet with or without bevacizumab; Biological · Drug
Lead sponsor: Genelux Corporation; Industry
Eligibility: 21 Years and older · Female only
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 2
States / cities: Newport Beach, California • Orlando, Florida

Conditions: Metastatic Pancreatic Adenocarcinoma
Interventions: Ibrutinib, Gemcitabine, Nab-paclitaxel; Drug
Lead sponsor: Pharmacyclics LLC.; Industry
Eligibility: 18 Years and older
Enrollment: 430 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 28
States / cities: Huntsville, Alabama • Avondale, Arizona • Daly City, California + 24 more

Conditions: Urothelial Carcinoma
Interventions: Carboplatin, Gemcitabine, Atezolizumab, Docetaxel; Drug
Lead sponsor: Nabil Adra; Other
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 4
States / cities: Indianapolis, Indiana • Omaha, Nebraska • Albuquerque, New Mexico + 1 more

Conditions: Acinar Cell Adenocarcinoma of the Pancreas, Duct Cell Adenocarcinoma of the Pancreas, Recurrent Pancreatic Cancer, Stage IV Pancreatic Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions: sorafenib tosylate, everolimus, laboratory biomarker analysis, pharmacogenomic studies, pharmacological study; Drug · Other
Lead sponsor: Roswell Park Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 2
States / cities: Aurora, Colorado • Buffalo, New York

Conditions: Lung Non-Small Cell Squamous Carcinoma, Stage IV Lung Cancer AJCC v8
Interventions: Berzosertib, Biospecimen Collection, Carboplatin, Computed Tomography, Gemcitabine Hydrochloride, Magnetic Resonance Imaging, Pembrolizumab; Drug · Procedure · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 34
States / cities: Los Angeles, California • Newport Beach, California • Aventura, Florida + 25 more

Conditions: TNBC - Triple-Negative Breast Cancer, Breast Cancer
Interventions: Trilaciclib, Placebo, Gemcitabine, Carboplatin; Drug
Lead sponsor: G1 Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 194 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 16
States / cities: Gilbert, Arizona • Washington D.C., District of Columbia • St. Petersburg, Florida + 13 more

Conditions: Metastatic Pancreatic Adenocarcinoma, Recurrent Pancreatic Carcinoma, Stage III Pancreatic Cancer AJCC v6 and v7, Stage IV Pancreatic Cancer AJCC v6 and v7
Interventions: Dasatinib, Erlotinib Hydrochloride, Gemcitabine Hydrochloride; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2027
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Small Cell Lung Cancer (SCLC)
Interventions: Nab-paclitaxel, Gemcitabine; Drug
Lead sponsor: Muhammad Furqan; Other
Eligibility: 18 Years to 99 Years
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Metastatic Pancreatic Carcinoma
Interventions: gemcitabine, capecitabine, erlotinib; Drug
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Advanced Biliary Tract Carcinoma
Interventions: Gemcitabine, Cisplatin, MEK162; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2019
U.S. locations: 1
States / cities: New York, New York

Conditions: Non-muscle Invasive Bladder Cancer (NMIBC)
Interventions: ABI-009, Gemcitabine; Drug
Lead sponsor: Aadi Bioscience, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 2
States / cities: New York, New York • Nashville, Tennessee

Conditions: Squamous Cell Carcinoma (SCC), Recurrent or Metastatic, Platinum-refractory Cervical Cancer
Interventions: Cemiplimab, Investigator Choice (IC) Chemotherapy; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 608 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2023
U.S. locations: 11
States / cities: Phoenix, Arizona • Tucson, Arizona • Orange, California + 8 more

Search by objective public record fields.

Testing the Addition of an Anti-Cancer Drug, Gemcitabine, to Usual Treatment (BCG Alone) in People Whose Non-Muscle Invasive Bladder Cancer (NMIBC) Came Back After Prior BCG Therapy

A Study for Participants With Pancreatic Cancer

Gemcitabine and Split-Dose Cisplatin Plus Everolimus (RAD001) in Patients With Advanced Solid Tumor Malignancies

Study of AG-270 in Participants With Advanced Solid Tumors or Lymphoma With MTAP Loss

A Study of PHST001 in Advanced Solid Tumors

A Study of Pre-Operative Cyberknife in Patients With Potentially Resectable Pancreas Cancer

Gemcitabine/Abraxane Chemotherapy and Dose Escalated Radiotherapy for Locally Advanced, Unresectable Pancreatic Cancer

Study of HuMab-5B1 (MVT-5873) in Subjects With Pancreatic Cancer or Other Cancer Antigen 19-9 (CA19-9) Positive Malignancies

Study of SBP-101 Combined With Nab-Paclitaxel and Gemcitabine in Pancreatic Cancer

Phase I Trial of 5-Azacitidine Plus Gemcitabine in Patients With Advanced Pancreatic Cancer

Paclitaxel Plus Gemcitabine in Treating Patients With Refractory Metastatic Germ Cell Tumors

A Study Evaluating IV Oncaspar® and IV Gemzar® in the Treatment of Solid Tumors and Lymphoma

Olvi-Vec Oncolytic Immunotherapy in Patients With Recurrent or Refractory Ovarian Cancer

Study of Ibrutinib vs Placebo, in Combination With Nab-paclitaxel and Gemcitabine, in the First Line Treatment of Patients With Metastatic Pancreatic Adenocarcinoma (RESOLVE)

Trial of Atezolizumab Plus Chemotherapy After Progression on PD-1 or PD-L1 in Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma

Sorafenib Tosylate and Everolimus in Treating Patients With Advanced Solid Tumors and Metastatic Pancreatic Cancer That Does Not Respond to Gemcitabine Hydrochloride

Testing the Addition of an Anti-cancer Drug, Berzosertib (M6620, VX-970), to the Usual Treatments (Carboplatin and Gemcitabine) and to Pembrolizumab for Patients With Advanced Squamous Cell Non-small Cell Lung Cancer

Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving Gemcitabine and Carboplatin for Metastatic Triple-Negative Breast Cancer (TNBC)

Gemcitabine Hydrochloride, Dasatinib, and Erlotinib Hydrochloride in Treating Patients With Pancreatic Cancer That Is Metastatic or Cannot Be Removed by Surgery

Nab-Paclitaxel With Gemcitabine for Relapsed Small Cell Cancer

A Phase I Trial of Capecitabine in Combination With Gemcitabine and Erlotinib for Advanced Pancreatic Cancer

First Line Gemcitabine, Cisplatin and MEK162 in Advanced Biliary Tract Carcinoma

Phase 1/2 Study of ABI-009 in Nonmuscle Invasive Bladder Cancer

Study of Cemiplimab in Adults With Cervical Cancer